Experimental study on the immune functions of splenic dendritic cells after a combined therapy of cryoablation and granulocyte macrophage-colony stimulating factor for prostate cancer

National Medical Journal of China

Volumn 91, Issue 17, 2011, Pages 1184-1187

  Si, Tong Guo ^a   Guo, Zhi ^a   Wang, Hai Tao ^a   Liu, Chang Fu ^a   Yang, Mao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Catheter ablation; Dendritic cells; Freezing; Prostatic neoplasms

Indexed keywords

LACTATE DEHYDROGENASE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CRYOABLATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; SPLEEN CELL; ANIMAL; CRYOSURGERY; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; PROSTATE TUMOR; SPLEEN; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CRYOSURGERY; DENDRITIC CELLS; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; PROSTATIC NEOPLASMS; SPLEEN;

EID: 84869789592     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.17.009     Document Type: Article

References (14)

1. Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology, 2009, 58: 1-11.
2. Si T, Guo Z, Hao X. Immunologic response to primary cryoablation of high-risk prostate cancer. Cryobiology, 2008, 57: 66-71.
3. 2010, 90: 952-955.
4. 2006, 23: 26-27.
5. Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol, 2008, 180: 1993-2004.
6. Pisters LL. Cryotherapy for prostate cancer: ready for prime time? Curr Opin Urol, 2010, 20: 218-222.
7. 2008, 42: 807-811.
8. den Brok MH, Sutmuller RP, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer, 2006, 95: 896-905.
9. Brusa D, Migliore E, Caretto S, et al. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate, 2009, 69: 1343-1352.
10. Machlenkin A, Goldberger O, Tirosh B, et al. Combined dendritic cell cryotherapy of tumor induce systemic antimetastatic immunity. Clin Cancer Res, 2005, 11: 4955-4961.
11. den Brok MH, Sutmuller RP, Nierkens S, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res, 2006, 66: 7285-7292.
12. McNeel DG. Prostate cancer immunotherapy. Curr Opin Uro, 2007, 17: 175-181.
13. Rini BI, Fong L, Weinberg V, et al. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol, 2006, 175: 2087-2091.
14. Sidana A, Chowdhury WH, Fuchs EJ, et al. Cryoimmunotherapy in urologic oncology. Urology, 2010, 75: 1009-1014.